Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03774914
Registration number
NCT03774914
Ethics application status
Date submitted
11/12/2018
Date registered
13/12/2018
Date last updated
25/04/2022
Titles & IDs
Public title
LEMTRADA Pregnancy Registry in Multiple Sclerosis
Query!
Scientific title
International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis
Query!
Secondary ID [1]
0
0
EU PAS - cat 3
Query!
Secondary ID [2]
0
0
OBS13436
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Observational [Patient Registry]
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Alemtuzumab (GZ402673)
Lemtrada - Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
Treatment: Drugs: Alemtuzumab (GZ402673)
Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Spontaneous abortions (=20 weeks gestation)
Query!
Assessment method [1]
0
0
Number and rate of spontaneous abortions on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [1]
0
0
32 weeks gestation
Query!
Secondary outcome [1]
0
0
Major congenital malformations
Query!
Assessment method [1]
0
0
Numbers and rates of major congenital malformations on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [1]
0
0
From birth to 1 year after delivery
Query!
Secondary outcome [2]
0
0
Minor congenital malformations
Query!
Assessment method [2]
0
0
Numbers and rates of minor congenital malformations on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [2]
0
0
From birth to 1 year after delivery
Query!
Secondary outcome [3]
0
0
Stillbirth (any non-deliberate foetal death at >20 weeks gestation)
Query!
Assessment method [3]
0
0
Numbers and rates of stillbirth, on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [3]
0
0
26-32 weeks' gestation to within 6 weeks after the end of the pregnancy
Query!
Secondary outcome [4]
0
0
Full-term live birth i.e. infants born maturely (=37 gestation weeks)
Query!
Assessment method [4]
0
0
Numbers and rates of full-term live birth on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [4]
0
0
Within 6 weeks after the end of the pregnancy
Query!
Secondary outcome [5]
0
0
Preterm birth i.e. infants born prematurely i.e., live-born infant i.e., (pre-term <37 weeks)
Query!
Assessment method [5]
0
0
Numbers and rates of pre-term birth on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [5]
0
0
26-32 weeks' gestation to within 6 weeks after the end of the pregnancy
Query!
Secondary outcome [6]
0
0
Elective terminations i.e. any induced or voluntary fetal loss
Query!
Assessment method [6]
0
0
Numbers and rates of elective terminations on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [6]
0
0
16-20 weeks' gestation
Query!
Secondary outcome [7]
0
0
Small for gestational age at birth i.e. birth size (weight, length, or head circumference) =10th percentile for gender and gestational age
Query!
Assessment method [7]
0
0
Numbers and rates of small for gestational age on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Query!
Timepoint [7]
0
0
Within 6 weeks after the end of the pregnancy
Query!
Secondary outcome [8]
0
0
Any other adverse pregnancy outcomes
Query!
Assessment method [8]
0
0
Numbers of adverse events
Query!
Timepoint [8]
0
0
Baseline to week 40
Query!
Secondary outcome [9]
0
0
Infant postnatal growth (up to the first year of life)
Query!
Assessment method [9]
0
0
Numbers and rates of infants with postnatal size (weight, length or head circumference) less than or equal to the 10th percentile for sex and age using National Center for Health Statistics (NCHS) pediatric growth curves, and adjusted postnatal age for premature infants.
Query!
Timepoint [9]
0
0
1 year after delivery
Query!
Secondary outcome [10]
0
0
Infant development impairment (up to the first year of life)
Query!
Assessment method [10]
0
0
Numbers and rates of infants with development impairment
Query!
Timepoint [10]
0
0
1 year after delivery
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
- Women with Multiple Sclerosis who were or became pregnant within the period of time
between the first infusion of a course of treatment with LEMTRADA to 4 months after
their last infusion for that course.
- Women able and willing to provide informed consent for study participation and the
requirement of the study. Informed consent will be obtained at the time of enrollment
in accordance with local regulatory requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Previous enrollment in this study for a previous pregnancy.
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/11/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
42
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Investigational Site Number :036001 - Box Hill
Query!
Recruitment postcode(s) [1]
0
0
3128 - Box Hill
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
New York
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Linz
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Charleroi
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Canada
Query!
Country [5]
0
0
Denmark
Query!
State/province [5]
0
0
Aarhus C
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Bochum
Query!
Country [7]
0
0
Italy
Query!
State/province [7]
0
0
Gallarate (VA)
Query!
Country [8]
0
0
Netherlands
Query!
State/province [8]
0
0
Netherlands
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Spain
Query!
Country [10]
0
0
Sweden
Query!
State/province [10]
0
0
Göteborg
Query!
Country [11]
0
0
Switzerland
Query!
State/province [11]
0
0
Zürich
Query!
Country [12]
0
0
United Kingdom
Query!
State/province [12]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genzyme, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
The primary goal of this registry is to assess the risk of spontaneous abortion in
prospective enrolled women exposed to LEMTRADA for multiple sclerosis.
Secondary Objective:
The secondary goals of this registry is to assess maternal, fetal and infant outcome in women
with multiple sclerosis, exposed to LEMTRADA.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03774914
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03774914
Download to PDF